Calvary Spine, LLC
$703.2K 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Day One Biopharmaceuticals
Day One Biopharmaceuticals reported $703,048.44 across General Payments, Research, and Ownership to 191 physicians and teaching hospitals across 441 transactions.
- $703.0K Above-median payer
- All-tracks total
- 441 Above-median volume
- Transactions
- 191 Above-median reach
- Recipients
- #694
- of 1,925 companies
Day One Biopharmaceuticals reported $703,048.44 across all CMS Open Payments tracks (General + Research + Ownership) to 191 physicians and teaching hospitals in Program Year 2024 - ranking #694 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $191,705.30, averaging $3.7K per recipient.
How Day One Biopharmaceuticals's $703.0K all-tracks total breaks down
Day One Biopharmaceuticals's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
26/100
Total payments
F
16/100
Transaction volume
F
13/100
Physician reach
F
11/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer day-one-biopharmaceuticals Day One Biopharmaceuticals
$703.0K · #694/1,925 · 0.0% industry · PY2024
- TOT $703.0K
- RANK #694
- SHARE 0.0%
- TXN 441
- RCP 191
- CAT 5
- GEN $191.7K
- TOP1 17.9%
- PY 2024
Volume peers
Nearest volume peer: Calvary Spine, LLC ($703.2K)
Day One Biopharmaceuticals sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Day One Biopharmaceuticals
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Day One Biopharmaceuticals, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 5-category general-payment breakdown below at $116.6K (60.8% of General Payments, 32 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Day One Biopharmaceuticals's 5-category general-payment breakdown at $116.6K, 60.8% of the reported total.
Day One Biopharmaceuticals reports 5 general-payment categories - the top three are Consulting Fee (60.8%), Compensation for Services Other Than Consulting (26.2%), and Travel and Lodging (8.3%). The remaining 2 categories make up 4.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Day One Biopharmaceuticals divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $116.6K | 32 | 60.8% |
| Compensation for Services Other Than Consulting | $50.3K | 15 | 26.2% |
| Travel and Lodging | $15.8K | 30 | 8.3% |
| Food and Beverage | $6.0K | 113 | 3.1% |
| Space Rental or Facility Fees | $3.0K | 1 | 1.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $109,218.65 (57.0%) of $191,705.30 in this company's General Payments records across 102 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Day One Biopharmaceuticals
The five named recipients with the highest reported General Payments from this company
- 1
Caroline Hastings
$34,245.90 across 26 reported transactions
- 2
Daniel Landi
$27,934.49 across 11 reported transactions
- 3
Amy Smith
$20,090.63 across 9 reported transactions
- 4
Bridget Archambault
$17,737.63 across 23 reported transactions
- 5
Mohamed Abdel-Baki
$9,210.00 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Day One Biopharmaceuticals ranks #694 of 1,925 by total payments (top 36% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,106 of 1,838 by HHI (bottom 40% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Aurora Spine, Inc. : $1.4M total payments, HHI 836
- Cardiva Medical, Inc. : $715.0K total payments, HHI 833
- Biocodex, Inc. : $25.0K total payments, HHI 832
- Kowa Research Institute, Inc. : $61.6K total payments, HHI 832
- Djo, LLC : $1.3M total payments, HHI 830
- Arcuro Medical Inc : $38.4K total payments, HHI 830
- Day One Biopharmaceuticals (this company) : $191.7K total payments, HHI 822
- Altus Partners. LLC : $374.7K total payments, HHI 817
- SIGN Fracture Care International : $6.8K total payments, HHI 815
- Septodont Inc. : $289.4K total payments, HHI 813
- BioHorizons Implant Systems Inc. : $1.4M total payments, HHI 813
- PTC Therapeutics, Inc. : $464.2K total payments, HHI 811
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Day One Biopharmaceuticals's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Day One Biopharmaceuticals.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Day One Biopharmaceuticals.
Showing 6 of 1,924 companies with CMS-reported payment data.
SurGenTec
$704.8K 249 recipients
Compare payment profiles
Napo Pharmaceuticals Inc
$704.8K 1,430 recipients
Compare payment profiles
Kuros Biosciences USA, Inc
$711.3K 1,447 recipients
Compare payment profiles
Kaneka Medical America LLC
$691.1K 202 recipients
Compare payment profiles
Scilex Pharmaceuticals Inc.
$715.7K 19,348 recipients
Compare payment profiles
Put this to use
Day One Biopharmaceuticals ranks #694 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Day One Biopharmaceuticals. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.